Utility of qSOFA score in identifying patients at risk for poor outcome in Staphylococcus aureus bacteremia

Emi Minejima¹, Vanessa Delayo¹, Mimi Lou¹, Pamela Ny², Paul Nieberg³, Rosemary C. She⁴ and Annie Wong-Beringer¹,²*

Abstract

Background: The prognostic capability of the quick Sequential Organ Failure Assessment (qSOFA) bedside scoring tool is uncertain in non-ICU patients with sepsis due to bacteremia given the low number of patients previously evaluated.

Methods: We performed a retrospective cohort study of adult hospitalized patients with Staphylococcus aureus bacteremia (SAB). Medical charts were reviewed to determine qSOFA score, systemic inflammatory response syndrome (SIRS) criteria, and Pitt bacteremia score (PBS) at initial presentation; their predictive values were compared for ICU admission within 48 h, ICU stay duration > 72 h, and 30-day mortality.

Results: Four hundred twenty-two patients were included; 22% had qSOFA score ≥ 2. Overall, mean age was 56y and 75% were male. More patients with qSOFA ≥ 2 had altered mentation (23% vs 5%, p < 0.0001), were infected with MRSA (42% vs 30%, p = 0.03), had endocarditis or pneumonia (29% vs 15%, p = 0.0028), and bacterial persistence ≥ 4d (34% vs 20%, p = 0.0039) compared to qSOFA < 2 patients. Predictive performance based on AUROC was better (p < 0.0001) with qSOFA than SIRS criteria for all three outcomes, but similar to PBS ≥ 2. qSOFA ≥ 2 was the strongest predictor for poor outcome by multivariable analysis and showed improved specificity but lower sensitivity than SIRS ≥ 2.

Conclusions: qSOFA is a simple 3-variable bedside tool for use at the time of sepsis presentation that is more specific than SIRS and simpler to calculate than PBS in identifying septic patients at high risk for poor outcomes later confirmed to have S. aureus bacteremia.

Keywords: S. aureus, Bacteremia, Mortality, Sepsis-3, qSOFA

Background

Sepsis is a significant cause of critical illness worldwide with an increasing incidence afflicting over 500,000 cases/year [1] and mortality rates up to 80% [2, 3]. Improved understanding of the pathobiology of sepsis has highlighted the heterogeneity in the host immune response in sepsis, prompting a need to redefine and update the clinical criteria to characterize the syndrome [4–7].

Sepsis is currently defined as a life-threatening acute organ dysfunction secondary to a dysregulated host response to infection (Sepsis-3) [6]. Previously, sepsis was defined as meeting ≥ 2 systemic inflammatory response syndrome (SIRS) criteria plus suspected infection. However, the SIRS definition was criticized for its lack of sensitivity; a recent study showed that 1 in 8 patients admitted to the intensive care unit (ICU) with severe sepsis did not meet the requisite minimum of 2 SIRS criteria to fulfill the sepsis definition [8]. Thus, to improve the identification of patients at risk for clinical deterioration from infection, Sepsis-3 recommends a quick scoring system, quick sequential organ failure assessment score (qSOFA), comprised of 3 elements

* Correspondence: anniew@usc.edu
¹Department of Clinical Pharmacy, University of Southern California School of Pharmacy, 1985 Zonal Ave, Los Angeles, CA 90089, USA
²Department of Pharmacy, Huntington Hospital, 100 W. California Blvd, Pasadena 91105, USA
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
assessed at the bedside (altered mental status, respiratory rate, and systolic blood pressure) and without the need for laboratory tests. Patients who show evidence of 2 out of 3 elements are considered positive for risk of clinical deterioration and therefore should prompt clinicians for investigation of organ dysfunction, initiation or escalation of therapy, and consideration of transfer of care to the ICU.

**Staphylococcus aureus** is the most common bacterial cause of sepsis in ICU patients [9]. *S. aureus* bacteremia (SAB) affects an estimated 50/100,000 population, with an overall mortality rate of 19–57% in adults [10]. Despite receipt of the standard treatment, persistent bacteremia occurs in one-third of patients beyond 7 days [11, 12], which can lead to metastatic complications, relapse, prolonged hospitalization, and increased mortality [11, 13–16].

Since Sepsis-3, the prognostic utility of qSOFA for in-hospital mortality has been prospectively validated in patients presenting to the emergency department with suspected infection [17], as well as retrospectively evaluated [18–26] but only a small number of evaluated patients had documented bacteremia. Thus, our study aims to evaluate non-ICU patients presenting with sepsis who later were confirmed to have *S. aureus* bacteremia for 1) differentiating clinical characteristics based on qSOFA score and 2) comparison of the predictive performance of qSOFA to SIRS criteria and Pitt bacteremia score (PBS) as a prognostic tool to identify those at high risk for poor outcome.

**Methods**

This was a 4-year retrospective cohort study conducted at three university-affiliated medical centers (600-bed community teaching, 600-bed county teaching, and 400-bed academic) in Los Angeles County, California. The study protocol was approved by the institutional review boards at each study site (University of Southern California and Quorum Review) and as the study was retrospective, informed consent was waived. Microbiology reports were screened for all patients with at least one positive blood culture for *S. aureus* between 2012 and 2016. Inclusion criteria were: 1) age ≥ 18 years, 2) receipt of ≥48 h of effective anti-staphylococcal therapy, 3) initiation of effective anti-staphylococcal therapy within 48 h from the time the first positive blood culture was drawn, 4) monomicrobial growth in the blood culture, and 5) not admitted to the ICU prior to or at onset of bacteremia. Patients with receipt of ≤48 h of effective therapy were excluded as assessment of therapy on mortality outcome was unlikely to be contributory to the antibiotic therapy given.

Medical charts were reviewed for relevant demographics including comorbidities, laboratory, radiographic data, surgical and antimicrobial management, and clinical data.

Extracted data were entered into a secure database, the Research Electronic Data Capture software hosted by University of Southern California.

**Study definitions**

qSOFA score was calculated for each patient using the worst value documented in the chart within the 24 h period of when the first positive blood culture for *S. aureus* was drawn for three clinical variables worth 1 point each: systolic blood pressure ≤ 100 mmHg, respiratory rate ≥ 22 breaths/min, and Glasgow coma score < 15 or altered mental status noted by the treating physician [6]. qSOFA score of ≥2 points was used as the prognostic cutoff value in predicting clinical deterioration (ICU admission within 48 h and ICU stay > 72 h) and death within 30 days. PBS was calculated for each patient at the onset of bacteremia to characterize the severity of illness based on 5 variables which included temperature, blood pressure, need for mechanical ventilation, evidence of cardiac arrest, and mental status [14]. The SIRS criteria and severity of sepsis were also evaluated according to the 2012 surviving sepsis campaign definitions [27].

The source of bacteremia was divided relative to risk of mortality: low (< 10%), intermediate (10–20%), and high (> 20%) as previously defined [28]. Antibiotic therapy was considered effective if antimicrobial sensitivity was documented. Early clinical response was evaluated on day 4 (72–96 h after initiation of effective antibiotic therapy) and determined as success or failure. Success was complete or partial resolution (objective signs of improvement without complete resolution) of fever, leukocytosis, local signs of infection, and clearance of blood cultures. Failure was defined as persistent growth of blood cultures and/or worsening in objective signs and symptoms of infection, including lack of resolution of fever, worsening or no improvement of leukocytosis, and/or lack of improvement of local signs of infection as documented by the treating physician. Mortality was defined as death occurring within 30 days from date of when the first positive blood culture was drawn.

**Data analysis**

Patients were grouped by high (≥ 2 points) or low (< 2 points) qSOFA scores as defined by Sepsis-3 criteria [6] and compared for demographics, clinical presentation and management, and outcomes. Endpoints for evaluation of prognostic capability were ICU admission within 48 h of SAB presentation, length of ICU stay > 72 h during the course of SAB, and 30-day mortality. The prognostic value of meeting at least two SIRS criteria [27] was compared to qSOFA score of ≥2. The positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of qSOFA score of ≥2, SIRS score ≥2, and PBS score ≥2 to predict each study...
endpoint were calculated. PBS score ≥ 2 was chosen based on the study by Hill et al. which showed a doubling of relative risk for mortality when PBS scores were 2 compared to patients with scores of < 2 in SAB [14]. A receiver operating characteristic (ROC) curve was created to calculate the corresponding area under the ROC (AUROC). Secondary endpoints included SAB outcomes of day 4 clinical failure and persistence of bacteremia past 4 days.

Descriptive analyses were conducted using Wilcoxon rank sum tests or student t test for continuous data and chi-square or Fisher’s exact test for categorical data. Univariate followed by multivariable logistic regression analysis were performed to determine the predictors of each outcome after controlling for age, gender, and source risk category. Only variables found to be significantly different between groups by univariate analysis were included in the multivariable logistic regression analysis for each primary endpoint. A p value < 0.05 was considered significant. Statistical analyses were performed using GraphPad Prism v4.0 (San Diego, CA, USA) or SAS version 9.4 (SAS Institute, Cary, NC).

Results

Study population
A total of 623 hospitalized patients with growth of S. aureus in a blood culture were screened; 402 patients met inclusion criteria. Two hundred and twenty-one patients were excluded for the following reasons: 3 patients were < 18 years old, 60 patients received < 48 h of effective antimicrobial therapy, 9 patients were initiated on antibiotics > 48 h from the first positive blood culture, 70 patients had polymicrobial blood cultures, 17 patients had incomplete medical charts, and 62 patients were admitted in the ICU > 24 h prior to the onset of bacteremia. Overall, demographics showed the mean age of 56 years, 75% were male, and 87% had community-onset bacteremia (Table 1). Nearly one quarter (22%, 90/402) of included patients had qSOFA scores ≥ 2 and were considered the high qSOFA group. Among those who acquired nosocomial SAB (n = 53), high qSOFA patients had longer duration of hospitalization prior to onset of bacteremia compared to the low qSOFA group (median 20 vs 9 days, p = 0.018). Regardless of qSOFA score, about half the patients (high 50% vs low 53%, p = 0.63) had history of three or more comorbidities as documented by the treating physician in the medical chart. Notably, a higher proportion of low qSOFA patients (10% vs 2%, p = 0.023) had no pre-existing comorbid condition per physician documentation in the medical chart. One third of patients had presence of hardware at the onset of SAB (high 33% vs low 30%, p = 0.53). Overall, MSSA was the predominant (67%) infecting pathogen. The high qSOFA group were more likely to be infected with MRSA (42% vs 30%, OR 1.72, 95% CI 1.06–2.79, p = 0.03) and twice as likely to have a high-risk source of bacteremia (29% vs 15%, OR 2.39, 95% CI 1.37–4.15, p = 0.0028). The high-risk sources were primarily endocarditis/endovascular source (16%) or pneumonia (11%) in the high qSOFA group. Skin and soft tissue (20%) and osteoarticular (20%) were the most common sources in the low qSOFA group.

Clinical presentation and management
The high qSOFA group had a sicker presentation at onset of bacteremia with higher proportion of patients with PBS ≥ 2 points (69% vs 12%, p < 0.0001). (Table 2) Nearly all (98%) patients in the high qSOFA group met SIRS criteria for sepsis compared to 74% in the low qSOFA group (p < 0.0001). In the high qSOFA group, respiratory rate ≥ 22 was the most frequent qSOFA criteria met (85% vs low qSOFA 24%, p < 0.0001), followed by systolic blood pressure ≤ 100 mmHg (68% vs low qSOFA 18%, p < 0.0001).

Overall, combination of vancomycin with a beta-lactam antibiotic for empiric therapy was the most common therapy administered (high 63% vs low 53%) though vancomycin monotherapy was more frequent in the low qSOFA group (29%) compared to the high qSOFA group (12%). Of the patients infected with MSSA, 76% (205/271) were treated with an anti-staphylococcal beta-lactam agent for definitive therapy, while MRSA bacteremia patients were treated with vancomycin in 59% (77/131) and daptomycin in 27% (36/131) as definitive therapy. There was a trend towards more patients in the high qSOFA group (78%) receiving effective therapy on or before the first day of positive blood culture (vs low 68%, p = 0.088). Duration of effective therapy during hospitalization was significantly longer in the high qSOFA group compared to the low qSOFA group (high 14 days vs low 8.5 days, p = 0.0011). Similar rates of patients in both groups received Infectious Disease (ID) consultation (high 52% vs low 58%, p = 0.33) with the same median of 2 days for time to receive consultation between the groups. Source control procedure for the SAB management was also similar in rates in both groups (high 40% vs low 49%, p = 0.12) with a median of 2 days to perform the procedure (high 2 days (IQR 1, 4.75) vs low 2 days (IQR 1, 4), p = 0.41).

Prognosis and outcome
Patients with high qSOFA score had significantly worse prognosis compared to those in low qSOFA group: ICU admission at any point after the onset of SAB was more frequent (64% vs 21%, p < 0.0001), more patients were transferred into the ICU within 48 h of onset of SAB (57% vs 16%, p < 0.0001), overall duration of ICU stay was prolonged by 2 days (median, p = 0.011), and a
significantly higher rate of ICU stays of > 72 h (48% vs 12%, \( p < 0.0001 \)). (Table 3) In addition, the high qSOFA group had higher rate of persistently positive blood cultures for \textit{S. aureus} despite receipt of \( \geq 4 \) days of effective therapy (34% vs 20%, \( p = 0.0039 \)), higher rate of 30-day mortality (19% vs 3%, \( p < 0.0001 \)), and a longer length of stay after the onset of SAB by 5 days (median) compared to the low qSOFA group (\( p = 0.001 \)). Among patients with initial high qSOFA scores, 49% experienced clinical failure at day 4 and were 11 times more likely to die than those showing early clinical response (34%, 15/44 vs 4%, 2/45, \( p = 0.0004 \); OR 11.12, 95% CI: 2.36–52.35).

### Table 1 Baseline Demographics comparing patients with high qSOFA score vs low qSOFA scores

| Characteristics                        | High qSOFA \( n = 90 \) (%) | Low qSOFA \( n = 312 \) (%) | \( p \) value |
|----------------------------------------|-----------------------------|-----------------------------|--------------|
| Age, yr. \( a \)                       | 56.5 ± 13.99                | 55.2 ± 15.1                 | 0.66         |
| Male                                   | 60 (67)                     | 241 (77)                    | 0.053        |
| Residence Prior to Admission           |                             |                             |              |
| Home                                   | 66 (73)                     | 240 (77)                    | 0.81         |
| Skilled Nursing Facility               | 5 (6)                       | 11 (4)                      |              |
| Other hospital/rehab center             | 9 (10)                      | 30 (10)                     |              |
| Homeless                                | 10 (11)                     | 31 (10)                     |              |
| Comorbid conditions                    |                             |                             |              |
| None                                   | 2 (2)                       | 30 (10)                     | 0.02         |
| Diabetes Mellitus                      | 35 (39)                     | 142 (46)                    | 0.28         |
| End stage renal disease on dialysis    | 16 (18)                     | 51 (16)                     | 0.75         |
| Cirrhosis                              | 11 (13)                     | 32 (11)                     | 0.52         |
| Cardiovascular disease \( b \)         | 40 (44)                     | 170 (54)                    | 0.096        |
| Immunosuppressed \( c \)               | 15 (17)                     | 37 (12)                     | 0.28         |
| \( \geq 3 \) comorbid conditions       | 45 (50)                     | 165 (53)                    | 0.63         |
| Race/Ethnicity                         |                             |                             | 0.18         |
| Caucasian                              | 28 (33)                     | 92 (30)                     |              |
| Asian                                  | 14 (16)                     | 26 (8)                      |              |
| African American                       | 10 (12)                     | 34 (11)                     |              |
| Hispanic                               | 32 (37)                     | 137 (44)                    |              |
| Other                                  | 2 (2)                       | 21 (7)                      |              |
| History of Intravenous Drug Use        | 13 (15)                     | 32 (10)                     | 0.26         |
| History of \textit{S. aureus} infection| 14 (16)                     | 57 (18)                     | 0.08         |
| History of IV vancomycin therapy       | 12 (13%)                    | 45 (15%)                    | 0.79         |
| Community-onset SAB                    | 77 (86)                     | 272 (87)                    | 0.72         |
| Microbial characteristics              |                             |                             | 0.03         |
| MSSA                                    | 52 (58)                     | 219 (70)                    |              |
| MRSA                                    | 38 (42)                     | 93 (30)                     |              |
| Source Risk Category \( d \)           |                             |                             | 0.0036       |
| Low risk                               | 20 (22)                     | 64 (21)                     |              |
| Intermediate risk                      | 43 (48)                     | 202 (65)                    |              |
| High risk                              | 26 (29)                     | 46 (15)                     |              |
| Study site                             |                             |                             | 0.43         |
| County teaching hospital               | 64 (71)                     | 205 (66)                    |              |
| Academic hospital                      | 11 (12)                     | 35 (11)                     |              |
| Community teaching hospital            | 15 (17)                     | 72 (23)                     |              |

\( a \) mean ± standard deviation; \( b \) Cardiovascular disease includes hypertension, dyslipidemia, congestive heart failure, coronary artery disease; \( c \) Immunosuppressed: malignancy, recent chemotherapy, chronic steroid use (prednisone \( \geq 20 \) mg/day or equivalent); SAB = \textit{S. aureus} bacteremia; \( d \) Sources of infection considered low risk were intravascular (IV) catheters, urinary tract infection, ear-nose-larynx, gynecologic, and several manipulation-related sources; intermediate risk were osteoarticular, soft-tissue, and unknown sources; and high risk were endovascular, lower respiratory tract, intra-abdominal, and central nervous system foci.
On the contrary, the mortality rate was only 8% (7/83) in the low qSOFA group who experienced early failure. Among those who died (n = 26), median time to death from initial positive blood culture was 10 days and 18 days for the high and low qSOFA group, respectively (p = 0.26). In a sub-analysis of patients in the high qSOFA group, those who died (n = 17) vs survived (n = 73) were older (mean age: 61.7y ± 3 vs 55.6y ± 1.7, p = 0.11), had more comorbid conditions (3 or more: 71% vs 45%, p = 0.11), received ID consultation (65% vs 49%, p = 0.29), and infection with MRSA (53% vs 40%, p = 0.42) but the differences observed did not reach statistical significance. However, rate of patients with ICU admission (88% vs 45%, p = 0.29) and need for vasopressors (88% vs 22%, p < 0.0001) were significantly more frequent in those who died vs survived.

Predictive performance of qSOFA, SIRS, and PBS clinical criteria

The predictive performance of qSOFA was compared to SIRS and PBS criteria and is shown in Fig. 1. qSOFA had a high specificity and negative predictive value with moderate to poor sensitivity and positive predictive values for all three endpoints, while the reverse was shown for SIRS criteria. The AUROC was significantly higher for qSOFA ≥2 compared to SIRS ≥2 for ICU admission within 48 h of onset of bacteremia [0.7 (95% CI 0.65–0.75) vs 0.6 (95% CI 0.54–0.62)], ICU stay longer than 72 h [0.7 (95% CI 0.64–0.76) vs 0.56 (95% CI 0.52–0.60)], and 30-day mortality [0.76 (95% CI 0.67–0.86) vs 0.54 (95% CI 0.47–0.62) (all comparisons p < 0.0001)]. The AUROC for qSOFA ≥2 was similar to PBS ≥2 for ICU admission within 48 h of onset of bacteremia [0.7 (95% CI 0.65–0.75) vs 0.7 (95% CI 0.65–0.75), p = 1], ICU stay > 72 h [0.7 (95% CI 0.64–0.76) vs 0.67 (95% CI 0.61–0.73), p = 0.34]), and 30-day mortality [0.76 (95% CI 0.67–0.86) vs 0.72 (95% CI 0.62–0.82), p = 0.46]. The most significant factors identified from the univariate analysis were evaluated in a multivariable model and controlled for age, gender, and source risk category. qSOFA scores ≥2 was the most significant predictor of each outcome in the model, with more than 4 times greater risk for poor outcome compared to those with qSOFA < 2 (Table 4). SIRS ≥2 was removed from the model as it was not significant. PBS ≥2 was a significant predictor for all three outcomes but the risk associated with qSOFA ≥2 was approximately two-fold greater for

### Table 2 Clinical Presentation at onset of *S. aureus* bacteremia

| Clinical Presentation | High qSOFA n = 90 (%) | Low qSOFA n = 312 (%) | p value |
|-----------------------|------------------------|-----------------------|---------|
| Pitt Bacteremia Score * | 2 (0, 3) | 0 (0, 1) | < 0.0001 |
| Score ≥ 2 | 57 (69) | 37 (12) | < 0.0001 |
| Score ≥ 4 | 19 (23) | 7 (2) | < 0.0001 |
| SIRS criteria | | | |
| Sepsis | 88 (98) | 232 (74) | < 0.0001 |
| Severe sepsis | 59 (66) | 86 (28) | < 0.0001 |
| Septic shock | 25 (28) | 3 (1) | < 0.0001 |
| No sepsis | 2 (2) | 80 (26) | |
| Presenting symptoms | | | |
| Fever | 35 (39%) | 100 (32%) | 0.25 |
| Pain | 28 (31%) | 155 (50%) | 0.0018 |
| Altered mental status | 21 (23%) | 16 (5%) | < 0.0001 |
| Shortness of breath | 10 (11%) | 19 (6%) | 0.11 |

* median (IQR), data available for 83 patients in High qSOFA group and 301 patients in the Low qSOFA group

### Table 3 Comparison of Clinical Outcomes of *S. aureus* bacteremia by qSOFA score

| Clinical Outcomes | High qSOFA n = 90 (%) | Low qSOFA n = 312 (%) | p value |
|-------------------|------------------------|-----------------------|---------|
| ICU admission | 58 (64) | 67 (21) | < 0.0001 |
| Need for vasopressors | 31 (35) | 17 (6) | < 0.0001 |
| Duration of ICU stay, days * | 5 (2, 123) | 3 (1, 7) | 0.01 |
| Duration of ICU stay > 72 h | 43 (48) | 38 (12) | < 0.0001 |
| Day 4 Success | 45 (50) | 228 (73) | < 0.0001 |
| Died | 2 (4) | 2 (1) | 0.07 |
| Day 4 Failure | 44 (49) | 83 (27) | < 0.0001 |
| Died | 15 (34) | 7 (8) | 0.0003 |
| Microbial Persistence on day 4 | 31 (34) | 62 (20) | 0.0039 |
| Died | 10 (32) | 3 (5) | 0.0007 |
| Initial GCS < 15 | 54/89 (61) | 31/306 (10) | < 0.0001 |
| Died | 13 (24) | 2 (6) | 0.04 |
| Initial SBP ≤ 100 mmHg | 57/84 (68) | 52/297 (18) | < 0.0001 |
| Died | 12 (21) | 3 (6%) | 0.026 |
| Initial RR ≥ 22 breaths per minute | 72/85 (85) | 71/298 (24) | < 0.0001 |
| Died | 14 (19) | 4 (6) | 0.021 |
| 30-day mortality | 17 (19) | 9 (3) | < 0.0001 |
| Total Hospital LOS, days * | 16 (8, 32) | 10 (6, 19) | < 0.0001 |
| LOS after first positive culture, days * | 14 (7, 38) | 9 (6.25, 17) | 0.001 |
| Disposition of survivors | | | |
| N = 73 | N = 303 | 0.92 |
| Home | 48 (66) | 198 (65) | |
| Skilled nursing facility | 12 (16) | 47 (16) | |
| Outside Hospital | 4 (5) | 23 (8) | |
| Rehab center | 7 (10) | 23 (8) | |
| Homeless/jail | 2 (3) | 12 (4) | |

ICU intensive care unit, LOS length of stay, GCS glasgow coma scale score, SBP systolic blood pressure, RR respiratory rate; * median (IQR)
the outcome of duration of ICU stay > 72 h and 30-day mortality.

Discussion
Sepsis-3 introduces qSOFA as a simple bedside tool for screening patients with suspicion of infection who are at increased risk for clinical deterioration [6]. Our study aimed to retrospectively evaluate the predictive performance of qSOFA scoring system in the setting of S. aureus bacteremia which has not been adequately studied previously.

Our findings are consistent with those from prior studies involving other infectious syndromes. Freund et al. prospectively evaluated the prognostic accuracy of qSOFA to predict poor outcomes in patients presenting to the emergency department with suspicion of infection. Similar to our study, they reported 24% of their study population had qSOFA scores ≥2 and that qSOFA had improved predictive performance compared to SIRS with AUROC of 0.73 (95% CI 0.68–0.77) for ICU admission, 0.71 (95% CI 0.66–0.76) for duration in ICU > 72 h, and 0.8 (95% CI 0.74–0.85) for in-hospital mortality [17]. In our study, those with initial qSOFA score of ≥2 were 8 times more likely to have prolonged ICU length of stay (> 72 h) and a fatal outcome when compared to patients with a qSOFA score < 2. We used another severity of illness score, PBS previously validated in SAB to predict mortality [14]. PBS scoring system uses 5 variables, 3 of which overlap with qSOFA (hypotension, mental status, and respiratory status) while the other 2 are temperature and evidence of cardiac arrest; the latter requires laboratory testing. Although similar variables are used in the PBS, parameters such as fever and altered mental status are stratified such that more points are assigned as the measured value is increasingly abnormal, whereas with qSOFA the points are assigned with a simple yes or no. The AUROC was comparable between qSOFA and PBS for each of the predefined outcomes. Considering that both PBS ≥2 and qSOFA ≥2 were shown to significantly predict the three clinical outcomes by multivariable logistic regression analysis, qSOFA would be a more

Table 4 Predictors of Outcome by Multivariable Logistic Regression

| Variable                      | ICU admission within 48 h of onset of SAB | p-value | OR (95% CI) | | Duration of ICU stay longer than 72 h | p-value | OR (95% CI) | | 30-day mortality | p-value | OR (95% CI) |
|-------------------------------|------------------------------------------|---------|-------------|-------------------------------|---------|-------------|-------------------------------|---------|-------------|
| Age                           | 0.99 (0.97–1.00)                         | 0.10    | 0.99 (0.97–1.00) | 0.13 | 1.03 (1.00–1.06) | 0.08 |
| Gender                        | 1.14 (0.62–2.11)                         | 0.68    | 1.04 (0.55–1.97) | 0.90 | 0.90 (0.34–2.42) | 0.84 |
| Source Risk Category: High vs. Intermediate & Low | 2.42 (1.27–4.59) | 0.007 | 2.01 (1.05–3.85) | 0.04 | 0.78 (0.26–2.29) | 0.65 |
| qSOFA ≥ 2                     | 4.40 (2.40–8.09)                         | < 0.0001 | 4.67 (2.51–8.68) | < 0.0001 | 6.94 (2.49–19.31) | 0.0002 |
| PBS ≥ 2                       | 4.69 (2.54–8.67)                         | < 0.0001 | 2.89 (1.53–5.48) | 0.001 | 3.38 (1.25–9.16) | 0.02 |

ICU intensive care unit, qSOFA quick sequential organ failure assessment, PBS pitts bacteremia score, OR odds ratio
practical tool for use at the bedside given its ease of use compared to PBS.

The goal of the qSOFA scoring system is to identify those at increased risk for clinical deterioration [29], and qSOFA score ≥ 2 had good negative predictive value and specificity in predicting prolonged ICU stay and 30-day all-cause mortality in patients with SAB, similar to prior studies [17, 21, 26]. Inversely, SIRS criteria has high sensitivity but was associated with high rate of false positives. Although qSOFA may lack sensitivity compared to SIRS in capturing patients who died, there were only 9 deaths in the low qSOFA group, of which 7 patients had non-SAB related deaths, including withdrawal of care. As SIRS criteria was criticized for lacking specificity which resulted in over-prescribing of antimicrobials, the increased specificity with qSOFA criteria supports its use to be a favored screening system to identify patients most likely to have poor outcome and therefore needing higher level of care.

MSSA was the predominant pathogen overall. Nonetheless, a significantly higher proportion of patients in the high qSOFA score (42%) was infected with MRSA. Notably, among patients with high qSOFA score, clinical outcomes were worse in those infected with MRSA compared to those with MSSA bacteremia: longer length of hospital stay and microbial persistence beyond 4 days of effective therapy. This is consistent with prior literature showing an association of worse outcomes with MRSA compared to MSSA bacteremia [30]. Despite the outcome difference observed between MSSA and MRSA-infected patients in our study, there was no significant difference seen in MRSA infected patients with high qSOFA scores in terms of initial PBS score, the proportions with high risk sources of SAB (MSSA 25% vs MRSA 34%, p = 0.48), and time to initiation of effective therapy compared to MSSA infected patients with high qSOFA scores. It is possible that inherent difference in antimicrobial efficacy and/or indirect immunomodulatory effects between agents used to treat MRSA and those (beta-lactams) available to treat MSSA bacteremia contributed to the outcome difference [30]. Taken together, results from our study adds to the existing data [17, 18, 20] in support of the use of qSOFA as a bedside tool in identifying non-ICU patients presenting with sepsis (including those later confirmed to have bacteremia due to *S. aureus*) for early and aggressive management.

Importantly, we found that in patients with persistent bacteremia, a high qSOFA score at initial presentation was associated with a 9 times higher risk of death than those with a low qSOFA. This finding is consistent with our previously published study in that a lack of early response in *S. aureus* bacteremia was the strongest predictor of treatment failure in a multivariable logistic regression model [31]. A trend towards higher risk of death was observed among those who continued on the same treatment despite lack of early response compared to those who switched to alternative therapy (mortality 38% vs 10%, *p* = 0.13). In addition, every additional day of persistently positive blood culture with *S. aureus* significantly increases the patient’s risk for mortality [32]. Thus, early recognition of high-risk patients using qSOFA could prompt clinicians to make a timely change in management including performing source control procedures earlier in the course to avoid negative outcomes. As the availability of rapid diagnostic technology has significantly shortened time to organism identification for bloodstream infection cases, early recognition of patients at high risk of poor outcome could allow antimicrobial stewardship teams to increase their vigilance of aiding clinicians to obtain early source control, screen for metastatic complications, obtain ID consultation, and initiate optimal antimicrobial therapy as soon as resistance information is known.

Our study has several limitations. As qSOFA scores were not used to prospectively guide therapeutic management in this study, we could not control for all confounding variables that may have affected the clinical outcomes. It is notable that similar proportion of patients between the high and low qSOFA groups received infectious disease consultation and source control procedure. While this study was conducted in the same geographic region, the number of patients included in this study was relatively large and included diverse patient populations such as the elderly and the medically underserved younger populations (age range 19–89 years). Our study population had a higher proportion of male over female patients which is consistent with prior epidemiologic studies, which found SAB to occur more frequently in male patients [33, 34]. We evaluated mortality within 30-days from onset of SAB, which is a common endpoint used in SAB studies while others employed in-hospital mortality as an endpoint in the sepsis literature. Only one patient in our study died past 30 days (died on day 46) after the onset of SAB. Thus, using an alternative definition of mortality did not affect our main analysis. Although at initial presentation of sepsis, the diagnosis of *S. aureus* bacteremia would not have been known, our study demonstrated that a high qSOFA score measured at initial presentation of sepsis predicted poor outcomes in this large cohort of patients who had confirmed *S. aureus* bacteremia later. Thus, if prospectively applied, qSOFA would likely demonstrate prognostic capability in patients with sepsis due to a variety of infection types, including bacteremia.

**Conclusion**

qSOFA is a simple 3-variable bedside tool that is more specific than SIRS and simpler to calculate than PBS in
identifying septic patients at initial presentation (later confirmed to have *S. aureus* bacteremia) who are at high risk for poor outcomes. Patients identified with high qSOFA score should receive aggressive management for infection including possible transfer to higher-level of care in the ICU. Future studies should include prospective evaluation of the utility of qSOFA scoring system in guiding antibiotic selection (e.g. need for MRSA coverage) particularly when combining with use of rapid diagnostic platform to confirm diagnosis of *S. aureus* bacteremia.

**Abbreviations**

AUCROC: area under the receiver operating characteristic; ICU: Intensive care unit; MRSA: Methicillin-resistant *S. aureus*; MSSA: Methicillin-sensitive *S. aureus*; NPV: Negative predictive value; PBS: Pitt bacteremia score; PPV: Positive predictive value; qSOFA: Quick sequential organ failure assessment; ROC: Receiver operating characteristic; SAB: Staphylococcus aureus bacteremia; SIRS: Systemic inflammatory response syndrome

**Acknowledgements**

We thank Anne Au and the lab personnel at Huntington Hospital, Los Angeles County-University of Southern California Medical Center, and Keck Hospital of USC for assistance with laboratory specimen collection; and Nancy Bui, Joshua Wang, Daniel Salas, Nicole Pepe, and Stephanie Mac for assisting with data collection.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available as data was collected through manual chart review from each institution’s electronic medical record and IRB approval to publish the raw data was not requested by the authors. Datasets are available from the corresponding author on reasonable request.

**Authors’ contributions**

EM, VD, and AWB collected and analyzed data, and were major contributors in writing of the manuscript. NL, PN2, and RS was involved with analyzing and interpreting the data and editing of the manuscript. PN1 was involved with data collection and editing of the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The study protocol was approved by the institutional review boards (IRB) at each respective study site (University of Southern California IRB for both Los Angeles County-University of Southern California Medical Center and Keck Hospital of Southern California; Quorum Review IRB for Huntington Hospital). As the study was non-interventional and there was no contact made with enrolled patients, the University of Southern California IRB and Quorum Review IRB allowed for informed consent to be waived. The study did not include enrolled patients, the University of Southern California IRB and Quorum Review IRB.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Clinical Pharmacy, University of Southern California School of Pharmacy, 1985 Zonal Ave, Los Angeles, CA 90089, USA. 2. Department of Pharmacy, Huntington Hospital, 100 W. California Blvd, Pasadena 91105, USA.

**References**

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546–54.
2. Javadi J, Lukšič I, Rafinson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2(1):010404.
3. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sak S, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.
4. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.
5. Jones RN. Microbiological etiologies of hospital-acquired pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81–7.
6. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
7. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–8.
8. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372(17):1629–38.
9. Vincent JL, Marshall JC, Nanesndrasilva SA, François B, Martin-Lopez C, Lipman J, Reinhard K, Antonelli M, Pickkers P, Njem J, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014;2(5):380–6.
10. van Hal SJ, Jensen SO, Vaska VL, Expedido BA, Paterson DL, Gossel IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362–85.
11. Hawkins C, Huang J, Jin N, Noskin GA, Ziembo BR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med. 2007;167(17):1861–7.
12. Chua T, Moore CL, Perri MB, Donabedian SM, Masch W, Vager D, Davis SL, Lulek K, Zimmnicki B, Zvorsk MJ. Molecular epidemiology of methillin-resistant *Staphylococcus aureus* (MRSA) bloodstream isolates in urban Detroit. J Clin Microbiol. 2008;46(7):2345–52.
13. Soriano A, Martínez JA, Men J, Marco F, Almela M, Moreno-Martínez A, Sánchez F, Muñoz J, Jiménez de Anta MT, Soriano E. Pathogenic significance of methillin resistance for patients with *Staphylococcus aureus* bacteremia. Clin Infect Dis. 2000;30(2):368–73.
14. Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, Murdoch D, Pottumurthy S, Roberts SA, Swager C, et al. Prospective study of 424 cases of *Staphylococcus aureus* bacteremia: determination of factors affecting incidence and mortality. Intern Med J. 2001;31(2):97–103.
15. Das I, O’Connell N, Lambert P. Epidemiology, clinical and laboratory characteristics of *Staphylococcus aureus* bacteremia in a university hospital in the United Kingdom. J Hosp Infect. 2007;65(2):117–23.
16. Chang FY,M, Peacock JE Jr, Musher DM, Triplett P, Mylko JM, O’Donnell A, Wagener MM, Yu VL. A prospective multicenter study of *Staphylococcus aureus* bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methillin resistance. Medicine (Baltimore). 2003;82(5):322–32.
17. Freund Y, Lencachetti N, Krsticnova E, Van Laer M, Claessens YE, Avondo A, Ocelli C, Feral-Pierssens AI, Truchot J, Ortega M, et al. Prognostic accuracy of *Sepsis-3* criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department. JAMA. 2017;317(3):301–8.
18. Chen YY, Wang JY, Guo SB. Use of CRB-65 and quick Sepsis-related organ failure assessment to predict site of care and mortality in pneumonia patients in the emergency department: a retrospective study. Crit Care. 2016;20(1):167.
19. Wang JY, Chen YX, Guo SB, Mei X, Yang P. Predictive performance of quick Sepsis-related organ failure assessment for mortality and ICU admission in patients with infection at the ED. Am J Emerg Med. 2016;34(9):1788–93.

20. Besen BA, Romanò TG, Nassar AP, Taniguchi LU, Azevedo LC, Mendes PV, Zampieri FG, Park M. Sepsis-3 definitions predict ICU mortality in a low-middle-income country. Ann Intensive Care. 2016;6(1):107.

21. Kim M, Ahn S, Kim WY, Sohn CH, Seo DW, Lee YS, Lim KS. Predictive performance of the quick sequential organ failure assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. Support Care Cancer. 2017;25(5):1557–62.

22. April MD, Aguirre J, Tannenbaum LJ, Moore T, Pingree A, Thaxton RE, Sessions DJ, Lantry JH. Sepsis clinical criteria in emergency department patients admitted to an intensive care unit: an external validation study of quick sequential organ failure assessment. J Emerg Med. 2017;52(5):622–31.

23. Giarelli-Bourboulis EJ, Tsagkis T, Tsangaris I, Lada M, Routsi C, Sinapidis D, Kouperis M, Bristianou M, Adamis G, Mandragos K, et al. Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2017;23(2):104–9.

24. Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AF, Lipman J. Systemic inflammatory response syndrome, quick sequential organ function assessment, and organ dysfunction: insights from a prospective database of ED patients with infection. Chest. 2017;151(3):586–96.

25. Rath EP, Udy AA, Bailey M, McGaughrin S, Macaulay C, Bellomo R, Pilcher D. (CORE) AaNZICSACfOaRE: prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290–300.

26. Churpek MM, Snyder A, Han X, Sokol S, Pettit N, Howell MD, Edelson DP. Quick Sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit. Am J Respir Crit Care Med. 2017;195(7):906–11.

27. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637.

28. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Menes J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193–200.

29. Vincent JL, Martin GS, Levy MM. qSOFA does not replace SIRS in the definition of sepsis. Crit Care. 2016;20(1):210.

30. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–9.

31. Joo J, Yamaki J, Lou M, Hsieh S, Chu T, Shinne KA, Wong-Beringer A. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy. Clin Ther. 2013;35(7):995–1004.

32. Rose WE, Eickhoff JC, Shulka SK, Pantrangi M, Roojakkens S, Cosgrove SE, Nizet V, Sakoulas G. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis. 2012;206(10):1604–11.

33. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763–71.

34. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis. 2008;198(3):336–43.